Italfarmaco's Givinostat Encouraging In DMD, But Awaiting 2022 Pivotal Study Results

CMO Bettica Outlines Development Approach

 
• By John Davis
  
Piazza del Duomo, Milan, Italy
Milan, where Italfarmaco is based • Source: Shutterstock/Viacheslav Lopatin

More from Rare Diseases

More from Scrip